Literature DB >> 15843085

Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.

G Carpino1, S Morini, S Ginanni Corradini, A Franchitto, M Merli, M Siciliano, F Gentili, A Onetti Muda, P Berloco, M Rossi, A F Attili, E Gaudio.   

Abstract

BACKGROUND: The alpha isotype of actin expressed by hepatic stellate cells reflects their activation to myofibroblast-like cell and has been directly related to experimental liver fibrogenesis, and indirectly to human fibrosis in chronic liver disease. AIMS: To evaluate the changes in distribution and percentage of alpha-smooth muscle actin-positive hepatic stellate cells and the correlation with the degree of the fibrosis in cirrhotic livers, as well as in patients with recurrent HCV chronic hepatitis after liver transplantation.
METHODS: Human liver biopsies were divided in four groups: (1) normal livers obtained from cadaveric liver donors (n=35), (2) cirrhosis post-HBV hepatitis (n=11), (3) cirrhosis post-HCV hepatitis (n=10), and (4) post-transplant recurrent HCV chronic hepatitis (n=13). Samples were stained with anti-alpha-smooth muscle actin antibody by immunoperoxidase method and semi-quantitatively evaluated. Liver fibrosis was assessed from specimens stained with Masson's trichrome and quantified by computer image analysis.
RESULTS: The percentage of alpha-smooth muscle actin-positive hepatic stellate cells was significantly higher in the HBV cirrhosis, HCV cirrhosis and post-transplant HCV recurrent hepatitis groups (36.1+/-15.2, 23.8+/-19.7 and 27.8+/-16.4%, respectively) compared to the liver donor group (2.9+/-4.0%). The alpha-smooth muscle actin-positive hepatic stellate cells to fibrous tissue ratio were significantly higher in the post-transplant recurrent HCV hepatitis group (2.36+/-1.12) compared to both the donor livers and the HCV cirrhosis groups (0.74+/-1.09 and 1.03+/-0.91, respectively). The alpha-smooth muscle actin-positive hepatic stellate cell percentage and fibrosis correlated positively in the post-transplant recurrent HCV hepatitis group and negatively in the HCV cirrhosis group. No difference in the immunohistochemical and morphometrical variables was found between the HCV cirrhosis and HBV cirrhosis groups.
CONCLUSIONS: These results indirectly confirm that, in vivo, alpha-smooth muscle actin expression is a reliable marker of hepatic stellate cells activation which precedes fibrous tissue deposition even in the setting of recurrent HCV chronic hepatitis after liver transplantation, and it could be useful to identify the earliest stages of hepatic fibrosis and monitoring the efficacy of the therapy. In the presence of advanced cirrhosis other factors, rather than alpha-smooth muscle actin-positive hepatic stellate cells, may sustain fibrosis deposition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843085     DOI: 10.1016/j.dld.2004.11.009

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  97 in total

1.  Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis.

Authors:  Maria Eduarda Rocha de França; Sura Wanessa Santos Rocha; Wilma Helena Oliveira; Laise Aline Santos; Anne Gabrielle Vasconcelos de Oliveira; Karla Patrícia Sousa Barbosa; Ana Karolina Santana Nunes; Gabriel Barros Rodrigues; Deniele Bezerra Lós; Christina Alves Peixoto
Journal:  Inflammopharmacology       Date:  2017-04-13       Impact factor: 4.473

Review 2.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway.

Authors:  Liu-Ya Tang; Mary Heller; Zhaojing Meng; Li-Rong Yu; Yi Tang; Ming Zhou; Ying E Zhang
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

4.  Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population.

Authors:  Zana Kalajzic; Haitao Li; Li-Ping Wang; Xi Jiang; Katie Lamothe; Douglas J Adams; Hector L Aguila; David W Rowe; Ivo Kalajzic
Journal:  Bone       Date:  2008-05-10       Impact factor: 4.398

5.  Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.

Authors:  Qiang Ou; Yuanyuan Weng; Siwei Wang; Yajuan Zhao; Feng Zhang; Jianhua Zhou; Xiaolin Wu
Journal:  Dig Dis Sci       Date:  2018-09-06       Impact factor: 3.199

6.  Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues.

Authors:  Leah M Norona; Deborah G Nguyen; David A Gerber; Sharon C Presnell; Edward L LeCluyse
Journal:  Toxicol Sci       Date:  2016-09-07       Impact factor: 4.849

7.  The Therapeutic Potential of Extracellular Vesicles Versus Mesenchymal Stem Cells in Liver Damage.

Authors:  Dina M Rostom; Noha Attia; Hoda M Khalifa; Maha W Abou Nazel; Eshrak A El Sabaawy
Journal:  Tissue Eng Regen Med       Date:  2020-06-06       Impact factor: 4.169

8.  Arg-gly-asp-mannose-6-phosphate inhibits activation and proliferation of hepatic stellate cells in vitro.

Authors:  Lian-Sheng Wang; Ying-Wei Chen; Ding-Guo Li; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  Inhibitory effects of rapamycin on the different stages of hepatic fibrosis.

Authors:  Yun Jeung Kim; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee; Seung Moo Noh; Dae Young Kang; Byung Seok Lee
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid.

Authors:  Richard M Dunham; Manoj Thapa; Victoria M Velazquez; Elizabeth J Elrod; Timothy L Denning; Bali Pulendran; Arash Grakoui
Journal:  J Immunol       Date:  2013-01-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.